Assenagon Asset Management S.A. Buys Shares of 90,931 Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Assenagon Asset Management S.A. bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 90,931 shares of the biopharmaceutical company's stock, valued at approximately $3,816,000. Assenagon Asset Management S.A. owned 0.16% of Celldex Therapeutics at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Wellington Management Group LLP raised its stake in shares of Celldex Therapeutics by 19.2% during the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company's stock valued at $256,860,000 after acquiring an additional 1,044,728 shares in the last quarter. Eventide Asset Management LLC raised its stake in shares of Celldex Therapeutics by 126.9% during the fourth quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company's stock valued at $143,966,000 after acquiring an additional 2,030,013 shares in the last quarter. Kynam Capital Management LP raised its stake in shares of Celldex Therapeutics by 23.1% during the third quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company's stock valued at $88,064,000 after acquiring an additional 600,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Celldex Therapeutics by 16.3% in the fourth quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company's stock worth $120,817,000 after buying an additional 427,827 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its stake in Celldex Therapeutics by 105.3% in the fourth quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company's stock worth $109,308,000 after buying an additional 1,413,722 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CLDX. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, May 15th. Guggenheim boosted their price objective on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the stock a "buy" rating in a research note on Tuesday, February 27th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Friday, March 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Celldex Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $66.00.

Celldex Therapeutics Price Performance

NASDAQ CLDX traded down $0.46 on Monday, hitting $37.75. The stock had a trading volume of 504,943 shares, compared to its average volume of 827,839. The business's fifty day moving average price is $40.23 and its 200 day moving average price is $38.02. Celldex Therapeutics, Inc. has a 52-week low of $22.11 and a 52-week high of $53.18. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of -13.25 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.19. The business had revenue of $4.13 million for the quarter, compared to analyst estimates of $1.20 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. As a group, sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -2.32 EPS for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.